Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
15-Oct-2026
REGION
Global
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
M1L7-01-00-00-00
SKU
HC_2026_34974
Yes
SHARE

Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026
Published on: 15-Oct-2026 | SKU: HC_2026_34974

Need more details?
$4,950.00
Need more details?

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, recombinant proteins, and other advanced biologics continue to expand global development pipelines, sponsors are seeking CDMOs capable of combining scientific expertise, operational excellence, regulatory reliability, and commercial-scale execution. This Frost Radar™ analysis examines the competitive dynamics shaping the mammalian CDMO landscape across the United States and Europe, evaluating how 16 leading CDMOs are responding to industry shifts including supply chain regionalization, technology-enabled manufacturing, process intensification, digitalization, and the preference for integrated development-to-commercialization service models. Drawing from Frost & Sullivan’s proprietary growth and innovation benchmarking methodology, the study provides a comprehensive assessment of market participants against the critical success factors that increasingly determine leadership in biologics outsourcing. These include biologics specialization, customer-centric development models, technology transfer efficiency, expertise in complex biologics, manufacturing resilience, and commercial readiness.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Author: Unmesh Lal

3PBIOVIAN

AGC Biologics

Avid Bioservices

Boehringer Ingelheim BioXcellence™

Catalent Biologics

Celonic

FUJIFILM Biotechnologies

Just-Evotec Biologics

KBI Biopharma

Lonza

mAbxience

Merck KGaA

Northway Biotech

ProBioGen AG

Rentschler Biopharma

Thermo Fisher Scientific

Significance of Being on the Frost Radar

CEO's Growth Team

Investors

Customers

Board of Directors

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Pharmaceuticals research

23 Sep 2026   |   Global   |   Technology Research

Programmable Epigenome Editing for Disease Reversal

Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applicati...

18 Sep 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Enabled Discovery and Diagnostics, Precision Therapeutics, and Next-Generation Vaccine Platforms

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming AI-enabled discovery, precision diagnostics, cell engineering, targeted therapeutics, vaccines, and skin health across oncology, metaboli...

07 Sep 2026   |   Global   |   Technology Research

Synthetic Antibodies and AI-Optimized Immunotherapies

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...

21 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Driven Biomanufacturing, Advanced Cell and Gene Therapies, and Precision Immunotherapy

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease...

31 Jul 2026   |   Global   |   Market Research

Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward speci...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, recombinant proteins, and other advanced biologics continue to expand global development pipelines, sponsors are seeking CDMOs capable of combining scientific expertise, operational excellence, regulatory reliability, and commercial-scale execution. This Frost Radar™ analysis examines the competitive dynamics shaping the mammalian CDMO landscape across the United States and Europe, evaluating how 16 leading CDMOs are responding to industry shifts including supply chain regionalization, technology-enabled manufacturing, process intensification, digitalization, and the preference for integrated development-to-commercialization service models. Drawing from Frost & Sullivan’s proprietary growth and innovation benchmarking methodology, the study provides a comprehensive assessment of market participants against the critical success factors that increasingly determine leadership in biologics outsourcing. These include biologics specialization, customer-centric development models, technology transfer efficiency, expertise in complex biologics, manufacturing resilience, and commercial readiness.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Author: Unmesh Lal
More Information
Deliverable Type Frost Radar
No Index No
Is Prebook No
Podcast No
Predecessor None
WIP Number M1L7-01-00-00-00

Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026

$4,950.00
Out of stock
SKU
HC_2026_34974